Efficacy of donepezil in early-stage Alzheimer disease:
a randomized placebo-controlled trial
by
Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D,
Ieni J, Richardson S; Donepezil "402" Study Group.
Department of Psychiatry and Neurology,
Tulane University School of Medicine,
1430 Tulane Avenue, New Orleans,
LA 70112-2699, USA.
seltzer@tulane.edu
Arch Neurol. 2004 Dec;61(12):1852-6

ABSTRACT

OBJECTIVE: To evaluate the efficacy of donepezil in patients with early-stage Alzheimer disease. DESIGN: Multicenter, randomized, double-blind, 24-week, placebo-controlled study that enrolled patients with early-stage Alzheimer disease. Patients were randomized in an approximately 2:1 ratio to donepezil, 5 mg/d, for the first 6 weeks, with a forced escalation to 10 mg/d thereafter (n = 96), or placebo (n = 57). The primary efficacy measure was the modified Alzheimer Disease Assessment Scale-cognitive subscale. Secondary efficacy measures included the Mini-Mental State Examination, the Computerized Memory Battery Test, the Clinical Dementia Rating Scale-Sum of the Boxes, the Patient Global Assessment Scale, and the Apathy Scale. RESULTS: Improvements favoring donepezil on the Alzheimer Disease Assessment Scale-cognitive subscale were found at weeks 12 and 24 and at the end point (last observation carried forward); treatment differences were 1.9 (P = .03), 2.3 (P = .008), and 2.3 (P = .001) points, respectively. Improvements favoring donepezil on the Mini-Mental State Examination were found at weeks 6, 12, and 24 and at the end point (last observation carried forward); treatment differences were 1.4 (P = .02), 1.2 (P = .04), 1.4 (P = .03), and 1.8 (P = .002) points, respectively. Donepezil-treated patients showed greater mean improvement compared with placebo-treated patients on the following Computerized Memory Battery Test subscales: facial recognition (P = .007 in the intent-to-treat population and P = .04 in the fully evaluable population), first and last name total acquisition (P = .02), and name-face association delayed recall (P = .04). Donepezil was safe and well tolerated in this population; serious adverse events occurred in similar numbers of donepezil- and placebo-treated patients. CONCLUSION: These data suggest significant treatment benefits of donepezil in early-stage Alzheimer disease, supporting the initiation of therapy early in the disease course to improve daily cognitive functioning.

Donepezil (Aricept)
Alzhemer's disease
The memory switch?
Dumb-drug euphoria
Growing new brain cells
Piracetam and working memory
Donepezil (Aricept) for the drug-addled
Alzheimer's Disease: resources and hotlinks
Donepezil ( Aricept ) for Alzheimer's disease

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Utopian Pharmacology
SMART DRUGS 2: review
The Hedonistic Imperative
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family